AHR and neoplasm: An additional AhR inhibitor, BAY-218 (from Bayer AG, Leverkusen, Germany), stimulated pro-inflammatory monocyte and T cell responses in vitro and anti-tumor responses in vivo in tumor models using CT16 and B16-OVA cell lines [124].